Humalog and Hepatocellular damage aggravated - a phase IV clinical study of FDA data

Summary:

Hepatocellular damage aggravated is reported as a side effect among people who take Humalog (insulin lispro recombinant), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Glucophage, and have Erection problems.

The phase IV clinical study analyzes which people have Hepatocellular damage aggravated when taking Humalog. It is created by eHealthMe based on reports of 136,521 people who have side effects when taking Humalog from the FDA, and is updated regularly.

What is Humalog?

Humalog has active ingredients of insulin lispro recombinant. It is often used in diabetes. eHealthMe is studying from 137,127 Humalog users. Check the latest studies of Humalog.

What is Hepatocellular damage aggravated?

Hepatocellular damage aggravated (serious liver damage) is found to be associated with 503 drugs and 192 conditions by eHealthMe. Check the latest studies of Hepatocellular damage aggravated.

On Jul, 26, 2026

136,521 people reported to have side effects when taking Humalog.
Among them, 44 people (0.03%) have Hepatocellular damage aggravated.

Could Humalog cause Hepatocellular damage aggravated?

Among these 44 people:

How long have people been on Humalog when they have Hepatocellular damage aggravated? *

What is the gender of people who have Hepatocellular damage aggravated when taking Humalog? *

female: 54.55 %
male: 45.45 %

What is the age of people who have Hepatocellular damage aggravated when taking Humalog? *

What are other drugs people take besides Humalog? *

What are other side effects people have besides Hepatocellular damage aggravated? *

Diabetes Mellitus Aggravated (serious diabetes): 10 people, 22.73%
Nausea (feeling of having an urge to vomit): 8 people, 18.18%
Hepatomegaly (abnormal enlargement of the liver): 8 people, 18.18%
Thrombocytopenia (decrease of platelets in blood): 8 people, 18.18%
Fatigue (feeling of tiredness): 8 people, 18.18%
Fatty Liver: 8 people, 18.18%
Weakness: 7 people, 15.91%
Diabetes Mellitus Inadequate Control: 7 people, 15.91%
Fever: 6 people, 13.64%
Blood Amylase Increased: 6 people, 13.64%

What are the existing conditions these people have? *

Pain: 2 people, 4.55%
Erection Problems: 2 people, 4.55%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 2.27%
Osteoporosis (bones weak and more likely to break): 1 person, 2.27%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 2.27%
Joint Pain: 1 person, 2.27%
Blood Glucose Decreased: 1 person, 2.27%
Acute Coronary Syndrome (acute chest pain and other symptoms that happen because the heart does not get blood): 1 person, 2.27%

* Approximation only. Some reports may have incomplete information.

Do you take Humalog and have Hepatocellular damage aggravated?

- Check whether Hepatocellular damage aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Humalog:

Humalog (137,127 reports)

Browse all side effects of Humalog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatocellular damage aggravated:

Hepatocellular damage aggravated (503 drugs)

Browse all the conditions that are associated with Hepatocellular damage aggravated:

Hepatocellular damage aggravated (192 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on insulin lispro recombinant (the active ingredients of Humalog) and Humalog (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.